{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:10:28Z","timestamp":1791043828731,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1124\/dmd.108.024489","type":"journal-article","created":{"date-parts":[[2009,2,18]],"date-time":"2009-02-18T21:09:06Z","timestamp":1234991346000},"page":"946-955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":131,"title":["The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice"],"prefix":"10.1016","volume":"37","author":[{"given":"Lin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick R.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Zelesky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Troutman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.108.024489_bib1","first-page":"4237","article-title":"The mouse Bcrp1\/Mxr\/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin","volume":"59","author":"Allen","year":"1999","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.108.024489_bib2","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/j.1471-4159.2007.04808.x","article-title":"Influence of breast cancer resistance protein (Abcg2) and P-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier","volume":"102","author":"Bihorel","year":"2007","journal-title":"J Neurochem"},{"key":"10.1124\/dmd.108.024489_bib3","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/0008-5472.CAN-04-2416","volume":"65","author":"Breedveld","year":"2005","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.108.024489_bib4","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1124\/dmd.31.3.312","article-title":"P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists","volume":"31","author":"Chen","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.024489_bib5","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1158\/0008-5472.CAN-03-2033","article-title":"Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier","volume":"64","author":"Cisternino","year":"2004","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.108.024489_bib6","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/00001756-200211150-00014","article-title":"Localisation of breast cancer resistance protein in microvessel endothelium of human brain","volume":"13","author":"Cooray","year":"2002","journal-title":"Neuroreport"},{"key":"10.1124\/dmd.108.024489_bib7","doi-asserted-by":"crossref","first-page":"6440","DOI":"10.1158\/1078-0432.CCR-07-1335","article-title":"P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan","volume":"13","author":"de Vries","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.108.024489_bib8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/dmd.104.001230","article-title":"The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A\/1B knockout mouse model","volume":"33","author":"Doran","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.024489_bib9","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.1038\/sj.onc.1206938","article-title":"Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)","volume":"22","author":"Doyle","year":"2003","journal-title":"Oncogene"},{"key":"10.1124\/dmd.108.024489_bib10","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1124\/dmd.107.019257","article-title":"Quantitative investigation of the role of breast cancer resistance protein (Bcrp\/Abcg2) in limiting brain and testis penetration of xenobiotic compounds","volume":"36","author":"Enokizono","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.024489_bib11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/dmd.107.017434","article-title":"In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system","volume":"36","author":"Feng","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.024489_bib12","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1124\/jpet.103.055574","article-title":"Interaction of imatinib mesylate with human P-glycoprotein","volume":"307","author":"Hamada","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.108.024489_bib13","doi-asserted-by":"crossref","first-page":"15649","DOI":"10.1073\/pnas.202607599","article-title":"The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria","volume":"99","author":"Jonker","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.108.024489_bib14","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.2002.12.116","article-title":"Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918","volume":"20","author":"Kruijtzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.108.024489_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2133\/dmpk.24.37","article-title":"In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney","volume":"24","author":"Kusuhara","year":"2009","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.108.024489_bib16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1124\/jpet.104.073320","article-title":"Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein","volume":"312","author":"Lee","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.108.024489_bib17","doi-asserted-by":"crossref","first-page":"7612","DOI":"10.1128\/MCB.24.17.7612-7621.2004","article-title":"Mrp4 confers resistance to topotecan and protects the brain from chemotherapy","volume":"24","author":"Leggas","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1124\/dmd.108.024489_bib18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1124\/dmd.104.001222","article-title":"Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice","volume":"33","author":"Maurer","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.108.024489_bib19","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal chemical properties of successful central nervous system drugs","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"NeuroRX"},{"key":"10.1124\/dmd.108.024489_bib20","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1359-6446(03)03003-4","article-title":"Holy grails and in vitro blood-brain barrier models","volume":"9","author":"Pardridge","year":"2004","journal-title":"Drug Discov Today"},{"key":"10.1124\/dmd.108.024489_bib21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1517\/17425255.1.2.233","article-title":"Expression and function of multidrug resistance transporters at the blood-brain barriers","volume":"1","author":"Scherrmann","year":"2005","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.108.024489_bib22","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0092-8674(94)90212-7","article-title":"Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs","volume":"77","author":"Schinkel","year":"1994","journal-title":"Cell"},{"key":"10.1124\/dmd.108.024489_bib23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s11095-006-9780-0","article-title":"Pharmacokinetic consequences of active drug efflux at the blood-brain barrier","volume":"23","author":"Syv\u00e4nen","year":"2006","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.108.024489_bib24","first-page":"6447","article-title":"The breast cancer resistance protein (Bcrp1\/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b ]pyridine","volume":"63","author":"van Herwaarden","year":"2003","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.108.024489_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/carcin\/bgi176","article-title":"Breast cancer resistance protein (Bcrp1\/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk","volume":"27","author":"van Herwaarden","year":"2006","journal-title":"Carcinogenesis"},{"key":"10.1124\/dmd.108.024489_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2009.02.007","article-title":"ABC transporter expression in brain microvessel endothelial cells and brain in five species including human","author":"Warren","year":"2009","journal-title":"Pharmacol Res"},{"key":"10.1124\/dmd.108.024489_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1021\/mp050088t","article-title":"A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line","volume":"3","author":"Xiao","year":"2006","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.108.024489_bib28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1021\/mp050113v","article-title":"Breast cancer resistance protein (Bcrp\/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse","volume":"3","author":"Zaher","year":"2006","journal-title":"Mol Pharm"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624020336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624020336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.108.024489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T11:36:21Z","timestamp":1739878581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624020336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0090955624020336"],"URL":"https:\/\/doi.org\/10.1124\/dmd.108.024489","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1157296.617432","asserted-by":"object"}]},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.108.024489","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2009 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}